Postmastectomy Radiotherapy for Locally Advanced Breast Cancer Receiving Neoadjuvant Chemotherapy
Table 1
Distribution of 170 breast cancer cases according to adjuvant radiotherapy.
Feature
Total
No PMRT
PMRT
value°
Age groups
≤40
33
18
15
41–50
62
25
37
51–60
5
18
32
>60
25
11
14
0.40
Clinical T classification
T1
4
2
2
T2
52
28
24
T3
48
27
21
T4
66
15
51
0.002
Clinical N classification
N0
42
20
22
N1
95
45
50
N2
33
7
25
0.024
Clinical stage
IIA
16
8
8
IIB
51
32
19
IIIA
35
17
18
IIIB
63
15
48
IIIC
3
—
5
0.0001
Multiple Foci
No
99
50
49
Yes
71
2
49
0.012
Pathologic T classification
pTx/pTis
14
7
7
pT1
26
13
13
pT2
75
39
36
pT3
18
7
11
pT4
37
6
31
0.007
Pathologic N classification
pN0
20
14
6
pN1
63
29
34
pN2
52
16
36
pN3
35
13
22
0.02
Downstage
No
115
43
72
Yes
55
29
26
0.07
Histology
Ductal invasive
118
55
63
Lobular invasive
36
12
24
Others
16
5
11
0.24
Pathologic skin involvement
Absent
136
66
70
Present
34
6
28
0.001
Extracapsular extension
Absent
115
52
63
Present
55
20
35
0.32
LVI
Absent
101
47
54
Present
69
25
44
0.21
Nuclear grading*
G1
11
6
5
G2
54
26
28
G3
80
33
47
0.58
Ki 67 index
<20
117
53
64
≥20
53
19
34
0.32
ER status
Negative
64
30
34
Positive
106
42
64
0.42
PgR status
Negative
83
40
43
Positive
87
32
55
0.16
NAC regimen
Anthracyclines-based
69
27
42
Anthracyclines and taxanes-based
93
44
49
No anthracyclines
8
1
7
0.13
Adjuvant hormonal therapy
No
62
28
34
Tamoxifen
75
31
44
AIs
33
13
20
0.89
Some data are missing; value from Fisher exact test or chi-square for trend, as appropriate. PMRT: postmastectomy radiotherapy; LVI: lymphovascular invasion; ER: estrogen receptors; PgR: progesterone receptors; NAC: neoadjuvant chemotherapy; AIs: aromatase inhibitors.
